Neoplasms

All Conditions

Skin and Connective Tissue Diseases

Rare Diseases

Chondrosarcoma

Neoplasms, Connective Tissue

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Sarcoma

Soft Tissue Sarcoma

Antineoplastic Agents

All Drugs and Chemicals

Ivosidenib

Enzyme Inhibitors

Participants will have locally advanced/metastatic or recurrent operable chondrosarcoma

AG-120 500 mg orally once daily days 1-28 of a 28-day cycle

AG-120

Ciara M Kelly, MBBCh, BAO

William D Tap, MD

Nara Sobreira, MD

Juan Manuel Schvartzman, MD, PhD

Gabriel Tinoco, MD

Anthony Conley, MD

This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.

AG-120 in People With IDH1 Mutant Chondrosarcoma

Phase II Study of AG-120 in IDH1 Mutant Chondrosarcoma

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Progression free survival includes both disease progression (as defined by RECIST 1.1) and death from any cause

Agios Pharmaceuticals, Inc.

Memorial Sloan Kettering Cancer Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
AG-120 in People With IDH1 Mutant Chondrosarcoma	NCT04278781	Chondrosarcoma Chondrosarcoma,... Chondrosarcoma,... IDH1 Gene Mutat...	AG-120	18 Years -	Memorial Sloan Kettering Cancer Center
AG-120 in People With IDH1 Mutant Chondrosarcoma	NCT04278781	Chondrosarcoma Chondrosarcoma,... Chondrosarcoma,... IDH1 Gene Mutat...	AG-120	18 Years -	Memorial Sloan Kettering Cancer Center

Spots Global Cancer Trial Database for chondrosarcoma, grade 2